Monday, Apr 19, 2021 | Last Update : 12:41 PM IST

  Business   Companies  06 Aug 2020  Novavax announces COVID-19 vaccine supply deal with Serum Institute

Novavax announces COVID-19 vaccine supply deal with Serum Institute

REUTERS
Published : Aug 6, 2020, 10:16 am IST
Updated : Aug 6, 2020, 10:16 am IST

Novavax reported that its experimental vaccine produced high levels of antibodies against coronavirus in a small, early-stage clinical trial

 Novavax signs Covid-19 vaccine supply deal with India's Serum Institute. (AFP Photo)
  Novavax signs Covid-19 vaccine supply deal with India's Serum Institute. (AFP Photo)

Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.

The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the “Pandemic Period” in all countries other than those designated by the World Bank as upper-middle or high-income countries.

 

The deal was signed on July 30, according to an SEC filing by Novavax.

On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.

Tags: covid-19, coronavirus, vaccine, novavax, serum institute